Isomorphic Labs Unveils AlphaFold3-Beating IsoDDE
💡Proprietary AI doubles AlphaFold3 accuracy on drug-protein binding; spots novel pockets for undruggable targets
⚡ 30-Second TL;DR
What Changed
IsoDDE doubles AlphaFold3 accuracy on challenging protein-ligand benchmarks
Why It Matters
Accelerates drug discovery by enabling precise, low-cost predictions of complex interactions, opening therapies for previously undruggable targets. Proprietary nature limits open research but signals DeepMind's commercial push.
What To Do Next
Review the IsoDDE technical report at https://zenodo.org/records/18606681 to benchmark against AlphaFold3 for protein modeling.
Key Points
- •IsoDDE doubles AlphaFold3 accuracy on challenging protein-ligand benchmarks
- •Outperforms Boltz-2 and physics methods on binding affinity predictions
- •Identifies novel brain protein cryptic sites from amino acid sequences only
- •Simulates induced fit and cryptic pockets beyond training data
- •Advances antibody-target interaction predictions for high-value therapies
🧠 Deep Insight
Background and context from public sources — not the original article. 6 sources cited.
🔑 Enhanced Key Takeaways
- •Isomorphic Labs was spun out from DeepMind in 2021 to apply AlphaFold technology commercially to drug discovery.
- •In 2024, Isomorphic Labs established major research collaborations with Novartis and Eli Lilly to advance AI-driven drug programs.
- •The company raised $600 million in April 2025 in its first external funding round, led by Thrive Capital, to build its drug design engine.[1]
🔮 Future ImplicationsAI analysis grounded in cited sources
⏳ Timeline
📎 Sources (6)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 机器之心 ↗
This is a summary, not the original. Read the source, or get the weekly briefing.
Weekly AI briefing
One email a week. Unsubscribe anytime.